Intellia Therapeutics: Buy Rating Driven by Promising Efficacy and Safety of Nex-Z Treatment
JonesTrading analyst Debanjana Chatterjee has reiterated their bullish stance on NTLA stock, giving a Buy rating on November 13. Debanjana ...